Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/05—Dipeptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/60—Sugars; Derivatives thereof
  • A61K8/602—Glycosides, e.g. rutin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/16—Emollients or protectives, e.g. against radiation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
  • A61K2800/81—Preparation or application process involves irradiation

Definitions

• the present invention relates to a combination comprising at least one bioflavonoid, in particular tiliroside and at least one peptide, in particular palmitoyl Lysine-valine-5-diaminohydroxybutyrate.
• the present invention also relates to a cosmetic or dermatological composition comprising this combination, as well as its use to prevent, delay or fight against aging of the skin and / or the appearance of signs of aging of the skin. In particular, this composition accelerates and / or stimulates the synthesis of type I collagen and also promotes the healing of the skin.
• the subject of the present invention is also a process for the cosmetic treatment of the skin.
• the skin In humans, anatomically, the skin consists of two main parts. The thin superficial part called the epidermis is attached to a thicker internal part, the dermis.
• the epidermis (etymologically formed in Greek of the words epi, sur and derma, skin) designates the tissue of epithelial nature which covers the dermis.
• the epidermis is composed mainly of three types of cells: keratinocytes, melanocytes and Langerhans cells.
• the epidermis is not irrigated by any blood vessel. The cells that compose it are fed by diffusion from the dermis. It contains, in contrast, many nerve endings.
• the dermis clearly separated from the epidermis by the "dermo-epidermic junction", continues in depth without any clear limit by the hypodermis.
• the dermis consists of different cell types and in particular fibroblasts, responsible for the synthesis and maintenance of extracellular material. They are cells of mesenchymal origin, which synthesize collagen, elastin, the basic substance and structural glycoproteins. Their activity is intense during healing phenomena.
• the dermis consists of a connective tissue that combines collagen fibers, elastic fibers and various cells embedded in an amorphous fundamental substance. It also contains the cutaneous appendages, which are the pilosebaceous follicles and the sweat glands, as well as vessels and nerves. By its fibers and its fundamental substance, the dermis contributes first of all to give the skin its mechanical properties: elasticity, resistance to impact, etc.
• Dermal fibers include collagen fibers and elastic fibers. They represent quantitatively the most important structural proteins of the dermis, respectively 75% and 5% of their dry weight. Their proportion relative and their arrangement are different depending on the superficial or deep areas of the dermis.
• Collagens are a very big family. These are extracellular matrix molecules composed of three polypeptide chains bearing the repetition of 3 amino acids:
• the "collagen fibers" of the dermis consist respectively of collagen I and collagen III, around an axis composed of collagen V. These collagens belong to the group of fibrillar collagens. In adults, collagen I is, on average, six times more abundant than collagen III.
• the collagen I / collagen III ratio decreases during aging. There is an exponential increase in chemical bridging between collagen fibers due to the non-enzymatic Maillard glycation reaction. This chemical bridging of the aged collagen results in an increasing stiffening of the fibers which makes them more resistant to attack by collagenases and by free radicals. Its degradation and renewal are thus slowed down.
• the fibroblast is a key cell of the connective tissue involved in the formation and stabilization of elastic fibers, but also in their dystrophy and lysis. During aging, the fibroblast decreases its activity and this resting cell is often called fibrocyte. It becomes globular, with a decrease in its cytoplasm and a rarefaction of its endoplasmic reticulum whose vesicles are very dispersed. The cytoskeleton takes on a fascicidal aspect. This cell is no longer in contact with collagen.
• the object of the present invention is to provide a product that can stimulate and / or accelerate the synthesis of type I collagen in a mammal and in particular in humans.
• Another aim of the present invention is to provide a product which makes it possible to treat, in a preventive or curative manner, a mammal in general, and in particular in humans, the aging of the skin and / or the appearance of the signs of the skin. aging of the skin.
• dermatological techniques for aesthetic purposes such as peels, lasers, pulsed flash lamps, radiofrequency treatments, LED treatments etc. has been observed.
• These cosmetic or dermatological treatment techniques can induce skin abrasion which then requires healing and / or fiber neosynthesis for dermal restructuring effects for anti-aging purposes.
• An object of the present invention is the provision of a product promoting the healing of the skin of a mammal and in particular a human being.
• the present invention also aims at providing a product which makes it possible, in a mammal and in particular in a human, during a cosmetic and / or dermatological treatment selected from the treatments mentioned above, to promote neosynthesis of collagen and optimize skin remodeling.
• Yet another object of the present invention is the provision of a cosmetic skin treatment method for preventing, delaying or controlling the appearance of signs of aging and / or age-related skin disorders and / or to promote the neosynthesis of collagen and / or to optimize skin remodeling during a dermatological treatment selected from a laser treatment, pulsed flash lamp treatment, radiofrequency treatment, LED treatment, a peel and a microdermabrasion.
• a dermatological treatment selected from a laser treatment, pulsed flash lamp treatment, radiofrequency treatment, LED treatment, a peel and a microdermabrasion.
• the Applicant has discovered a combination comprising at least one bioflavonoid, more particularly tiliroside, and at least one peptide, palmitoyl Lysine-Valine-5-diaminohydroxybutyrate or Palm-Lys-Val-Dab-OH, with properties advantageous.
• the Palm-Lys-Val-Dab-OH peptide is known in the prior art for its biological actions such as the stimulation of the synthesis of laminin V and the stimulation of the synthesis of collagen I. It is described for its applications in as an anti-aging, anti-wrinkle and repairing active ingredient.
• Tiliroside has already been described in the prior art as an anti-aging active for sensitive skin and as a protective agent against oxidative stress and micro-inflammation processes. It is also known for its antiallergic, anti-elastase and anti-collagenase properties.
• tiliroside is described and claimed as a UV filter, antioxidant agent, anti-free radical agent, active against oxidative stress, anti-aging, anti-allergic, anti-inflammatory and anti-inflammatory agent.
• UV filter EP 1 393 733 describes tiliroside for the treatment of atopic eczema.
• a composition comprising tiliroside for treating conditions affecting collagen is mentioned.
• a remarkable property of the combination of the present invention is that it has effects in greater proportions than those reasonably expected from the mere addition of the effects of each of these compounds taken separately.
• the present invention relates to a combination comprising at least one bioflavonoid, tiliroside and at least one peptide, palmitoyl Lysine-valine-diaminohydroxybutyrate.
• Tiliroside (C 30 H 26 O 7 ) is a known and commercially available compound. For the implementation of the present invention, it can be used pure or in the form of a plant extract. It is marketed by Merck KgaA in more than 95% purified form. WO 2006/099930 describes the preparation of tiliroside from plants.
• Palmitoyl Lysine-Valine-diaminohydroxybutyrate is marketed by Pentapharm in a 0.2% solution in a hydro-glycerine solvent.
• the weight percentage of tiliroside (T) relative to palmitoyl Lysine-5-valine diaminohydroxybutyrate (P), T / P is between 0.1 and 1000, preferably between 0.25 and 200.
• the present invention also relates to a cosmetic and / or dermatological composition comprising an association as described above in a cosmetically or dermatologically acceptable support.
• Cosmetically acceptable carriers that is to say, supports compatible with the skin are in all the forms known by the human being. and normally used for topical application, especially in the form of an oil-in-water or water-in-oil emulsion, an aqueous, oily or aqueous-alcoholic solution, an aqueous or oily gel, a liquid, pasty or solid anhydride product, an oil dispersion in an aqueous phase.
• the composition of the invention may also contain adjuvants usually used in the cosmetic and dermatological fields such as hydrophilic or lypophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, filters, fillers. , pigments, chelating agents and dyes.
• composition of the invention may be in the form of creams, gels, serums, lotions, milks or oils. It can, if necessary be applied to the skin in the form of an aerosol. It can also be in solid form, for example in the form of a stick.
• this composition comprises 0.01 to 10% by weight of tiliroside and 0.0001 to 1% by weight of palmitoyl Lysine-5-valine diaminohydroxybutyrate.
• the composition comprises 0.01 to 1% by weight of tiliroside and 0.005 to 0.5% by weight of palmitoyl Lysine-5-valine diaminohydroxybutyrate.
• the composition comprises 0.05 to 0.5% by weight of tiliroside and 0.001 to 0.1% by weight of palmitoyl Lysine-5-valine diaminohydroxybutyrate.
• the composition according to the present invention is used to stimulate and / or accelerate the synthesis of type I collagen. This stimulation and / or acceleration of collagen I synthesis is due to the synergistic effect of the combination of tiliroside and palmitoyl. Lysine-5-valine diaminohydroxybutyrate.
• composition of the present invention can be used in all circumstances where neo collagen synthesis is desired.
• composition according to the present invention can be used to prevent, delay or fight against aging of the skin and / or the appearance of signs of aging of the skin
• signs of aging of the skin is meant all the changes in the external appearance of the skin due to chronological aging and photo induced.
• These signs of skin aging are, for example, the appearance of fine lines and wrinkles, sagging skin, wilted skin, thinned skin, and dull and / or lackluster skin, lack of elasticity and / or tone of the skin.
• the signs of skin aging may also be mentioned all the internal changes in the skin that do not systematically result in a modified external appearance, for example all internal skin damage and in particular the degradation of collagen.
• the appearance of stretch marks due to the breakdown of collagen fibers and elastic fibers following in particular a too rapid and too abrupt stretching of the skin can also be prevented and / or treated by the composition of the invention.
• Stretch marks appear frequently during pregnancy or as a result of significant weight change or even rapid growth.
• Certain cosmetic and / or dermatological treatments for aesthetic purposes may induce skin abrasion requiring cicatrization and / or neosynthesis of collagen to optimize skin remodeling.
• These treatments include laser treatment, pulsed flash lamp treatment, radiofrequency therapy, light emitted diode (LED) treatment, peeling and microdermabrasion.
• LED light emitted diode
• the treatments with dermatological or cosmetic lasers are aimed at preventing and treating skin aging.
• Ablative lasers have the principle of destroying very thin layers of skin. During treatment, the laser light volatilizes the epidermis and the most superficial part of the dermis. These two thicknesses are thus eliminated. In the dermis, it is mainly the altered elastin fibers that are removed, but there is also a thermal effect that leads to the formation of new collagen fibers.
• the lasers used here are CO 2 and / or erbium lasers.
• the CO 2 laser (10 600 nm) used in continuous mode induces cutaneous abrasion with coagulation and is preferentially aimed at a marked photoaging. Healing takes about 7 days.
• the pulsed Er-Yag laser (2 950 nm), purely ablative (without coagulation, hence induction of bleeding), induces a lighter resurfacing and is intended for less marked photoaging. Healing is faster (eviction of about 7 days). Remodeling lasers and rejuvenation lamps give more modest results and virtually no side effects.
• remodeling lasers induce a neo synthesis of collagen. They improve the tone and texture of the skin and smooth the relief (fine lines).
• Devices are used whose wavelength is preferentially absorbed either by the water of the dermis or by the superficial vessels of the dermis.
• fractional resurfacing fractional photothermolysis
• This technique is based on a laser (1500 min) that does not scan the entire surface but achieves impacts of 100 microns in diameter. At each session, 20% of the dermis is treated. Healing is rapid (moderate erythema associated with a pseudo-bronzed appearance).
• RF (painful) radiotherapy treatments and the 1100 to 1800 nm infrared light are used to prevent and / or treat sagging skin.
• the peel is another non-surgical technique that eliminates a precise and controlled skin thickness, induces a healthy regeneration of the destroyed layer and anabolic stimulation of the underlying layers.
• the peels are classified as light, medium and deep depending on the destroyed skin layer. The complications due to peeling are all the more serious as the peel is deep.
• Microdermabrasion includes the projection of alumina hydroxide crystals and aspiration.
• One can play on the power of aspiration, the speed of projection and the number of passages on the same zone to modulate the abrasion which can be epidermal (exfoliation of the stratum corneum), superficial dermal (with or without bleeding), dermal (with bleeding).
• composition according to the present invention can be used to stimulate and / or promote healing.
• it can be used to promote or stimulate healing after a cosmetic or dermatological treatment such as those described above. But it can also be used to promote or stimulate the healing of a lesion due to injury or surgery.
• composition that is the subject of the invention can also be used to promote the neosynthesis of collagen and to optimize skin remodeling during a dermatological or cosmetic treatment selected from among a laser treatment, a pulsed flash lamp treatment, and a radiofrequency treatment , a treatment with LED, a peel and a microdermabrasion.
• a dermatological or cosmetic treatment selected from among a laser treatment, a pulsed flash lamp treatment, and a radiofrequency treatment , a treatment with LED, a peel and a microdermabrasion.
• this composition can be used as a healing product to accompany treatments such as laser treatments, peeling, microdermabrasion etc. In this case, it is applied to the skin after the cosmetic or dermatological treatment and the application is repeated repeatedly with a frequency that can range from 1 to 5 times per day and until a satisfactory result is obtained. .
• the composition according to the present invention can also be used during one of the treatments mentioned above on the treated areas, to optimize the performance of the treatments (for example: rejuvenation).
• the composition of the invention has a potentiating effect which enhances the action of dermatological or cosmetic treatment. In this case, the composition is applied to the cutaneous area to be treated shortly before (a few minutes or a few hours) the beginning of each act of the cosmetic or dermatological treatment.
• composition of the present invention can also be used alternately with each act and / or after the treatment to optimize the effectiveness of aesthetic treatments.
• the frequency and duration of treatment with this composition are adapted according to the individual and the cosmetic and / or dermatological treatment applied.
• composition of the invention can be used daily as an anti-aging product or promoting healing.
• the present invention also relates to a method of cosmetic treatment of the skin to prevent, delay or fight against age-related skin disorders and / or the appearance of signs of skin aging, to promote healing and / or the neosynthesis of collagen and to optimize skin remodeling during a dermatological treatment selected from laser treatment, pulsed flash lamp treatment, radiofrequency treatment, LED treatment, peeling and microdermabrasion, said method comprising the application on the skin of the composition forming the subject of the present invention.
• This application can be made before the dermatological or cosmetic treatment, it can intervene between two acts of this treatment or it can be posterior to this treatment.
• This application on the cutaneous areas concerned can be repeated with a frequency and for a duration that the skilled person can adapt according to the individual and the associated dermatological or cosmetic treatment.
• FIG. 1 represents the synergistic effect of the combination of tiliroside and palmitoyl Lysine-5-valine diaminohydroxybutyrate on the synthesis of type I collagen in normal adult human fibroblasts.
• the fibroblasts were seeded in 6-well plates with glass coverslip at a rate of 70,000 cells per dish in MEM medium (Minimum Essential Medium). 48 hours later, the cells were treated or not (control) with palmitoyl
• the cells are incubated with the first anti-collagen antibody I
• This fluorescence intensity is related to the number of cells per plate.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Dermatology (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Birds (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Immunology (AREA)
• Gastroenterology & Hepatology (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Toxicology (AREA)
• Cosmetics (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=40202183

Family Applications (1)

Country Status (8)

Cited By (1)

Families Citing this family (4)

Citations (2)

Family Cites Families (1)

• 2008
  • 2008-06-19 FR FR0803425A patent/FR2932680B1/fr not_active Expired - Fee Related
• 2009
  • 2009-06-18 CA CA2728155A patent/CA2728155A1/fr not_active Abandoned
  • 2009-06-18 EP EP09766021.1A patent/EP2310031B1/fr active Active
  • 2009-06-18 ES ES09766021.1T patent/ES2445202T3/es active Active
  • 2009-06-18 AU AU2009261809A patent/AU2009261809B9/en not_active Ceased
  • 2009-06-18 US US12/999,971 patent/US20110144565A1/en not_active Abandoned
  • 2009-06-18 WO PCT/FR2009/000732 patent/WO2009153459A1/fr not_active Ceased
  • 2009-06-18 JP JP2011514087A patent/JP5642068B2/ja not_active Expired - Fee Related

Patent Citations (2)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events